JP2017530176A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530176A5
JP2017530176A5 JP2017518804A JP2017518804A JP2017530176A5 JP 2017530176 A5 JP2017530176 A5 JP 2017530176A5 JP 2017518804 A JP2017518804 A JP 2017518804A JP 2017518804 A JP2017518804 A JP 2017518804A JP 2017530176 A5 JP2017530176 A5 JP 2017530176A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
group
independently selected
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017518804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530176A (ja
JP6820254B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/091614 external-priority patent/WO2016055028A1/en
Publication of JP2017530176A publication Critical patent/JP2017530176A/ja
Publication of JP2017530176A5 publication Critical patent/JP2017530176A5/ja
Application granted granted Critical
Publication of JP6820254B2 publication Critical patent/JP6820254B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017518804A 2014-10-10 2015-10-10 治療用化合物およびその使用 Expired - Fee Related JP6820254B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014088315 2014-10-10
CNPCT/CN2014/088315 2014-10-10
PCT/CN2015/091614 WO2016055028A1 (en) 2014-10-10 2015-10-10 Therapeutic compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2017530176A JP2017530176A (ja) 2017-10-12
JP2017530176A5 true JP2017530176A5 (OSRAM) 2018-11-22
JP6820254B2 JP6820254B2 (ja) 2021-01-27

Family

ID=55652608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518804A Expired - Fee Related JP6820254B2 (ja) 2014-10-10 2015-10-10 治療用化合物およびその使用

Country Status (5)

Country Link
US (1) US10206931B2 (OSRAM)
EP (1) EP3204360B1 (OSRAM)
JP (1) JP6820254B2 (OSRAM)
CN (1) CN107108512B (OSRAM)
WO (1) WO2016055028A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108613B (zh) * 2014-11-10 2020-02-25 基因泰克公司 布罗莫结构域抑制剂及其用途
EA201891620A1 (ru) 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
CN115028617A (zh) * 2016-05-24 2022-09-09 基因泰克公司 Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
EP3487993A1 (en) 2016-07-25 2019-05-29 Epizyme, Inc. Crebbp related cancer therapy
PL3552017T3 (pl) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN107325092B (zh) * 2017-08-07 2021-01-08 山东鲁宁药业有限公司 一种阿奇沙坦的制备新工艺
CN107643405B (zh) * 2017-09-19 2020-07-17 上海市肺科医院 一种基于自身抗体检测的肺癌诊断试剂盒及其应用
WO2019070742A1 (en) * 2017-10-03 2019-04-11 Sidecar Therapeutics, Inc. APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITORS COMPOUNDS
BR112020019824A2 (pt) 2018-03-29 2021-01-05 Board Of Regents, The University Of Texas System Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
CN113646002A (zh) * 2019-02-27 2021-11-12 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
SMT202400386T1 (it) * 2019-02-27 2024-11-15 Constellation Pharmaceuticals Inc Derivati di n-(piridinil)acetammide come inibitori di hat p300/cbp e metodi per il loro utilizzo
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
EP3986470A4 (en) * 2019-06-18 2023-10-04 Dana-Farber Cancer Institute, Inc. SMALL MOLECULE TARGET BROMO/ACETYL PROTEINS AND THEIR USES
CN110170052B (zh) * 2019-06-21 2020-07-10 复旦大学 Cbp-p300抑制剂在肠道损伤疾病中的应用
TW202120095A (zh) * 2019-08-05 2021-06-01 美商美國禮來大藥廠 7,8-二氫-4H-吡唑并[4,3-c]氮呯-6-酮化合物
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
JP7462071B2 (ja) * 2020-04-25 2024-04-04 南京薬石科技股▲フン▼有限公司 Cbp/ep300阻害剤及びその使用
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
TW202210472A (zh) 2020-06-05 2022-03-16 美商奇奈特生物製藥公司 纖維母細胞生長因子受體激酶之抑制劑
US20230250088A1 (en) * 2020-07-15 2023-08-10 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP4277897A1 (en) * 2021-01-12 2023-11-22 Chengdu Anticancer Bioscience, Ltd. Fused azepine compounds and their use in the treatment of cancer
WO2022226172A1 (en) * 2021-04-21 2022-10-27 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
WO2022231262A1 (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제의 제조 방법
WO2023088420A1 (en) * 2021-11-19 2023-05-25 Chengdu Anticancer Bioscience, Ltd. 1h-benzo[b]azepin-2(3h)-one compounds, compositions and methods of treating cancer
MX2024008648A (es) 2022-01-12 2024-09-23 Denali Therapeutics Inc Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3203952A (en) * 1962-12-04 1965-08-31 Upjohn Co Chloromethylsulfonamides of cyclic diamines
US3361750A (en) * 1963-03-21 1968-01-02 Squibb & Sons Inc Benzothiazepines
DE3800386A1 (de) * 1988-01-09 1989-07-20 Bayer Ag Verfahren zur herstellung von benzothiazepinon-derivaten
US20080076760A1 (en) * 2004-11-10 2008-03-27 Wakamoto Pharmaceutical Co., Ltd 2,3,4,5-tetrahydro-1h-1,5-benzodiazepine derivative and medicinal composition
DE102006051796A1 (de) * 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate
EP2705039B1 (en) * 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI530499B (zh) * 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類

Similar Documents

Publication Publication Date Title
JP2017530176A5 (OSRAM)
JP2019516757A5 (OSRAM)
JP2019516759A5 (OSRAM)
JP2017533250A5 (OSRAM)
JP2017537100A5 (OSRAM)
JP2017526696A5 (OSRAM)
JP2018501287A5 (OSRAM)
JP2017533249A5 (OSRAM)
JP2018510851A5 (OSRAM)
JP2017530984A5 (OSRAM)
JP2017533248A5 (OSRAM)
JP2017525740A5 (OSRAM)
JP2018507191A5 (OSRAM)
JP2018505169A5 (OSRAM)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2016529312A5 (OSRAM)
JP2016510748A5 (OSRAM)
JP2017121233A5 (OSRAM)
JP2016513137A5 (OSRAM)
JP2014506601A5 (OSRAM)
JP2010522194A5 (OSRAM)
RU2015142102A (ru) Соединение для лечения рака
JP2013507415A5 (OSRAM)
JP2019522055A5 (OSRAM)
JP2017502092A5 (OSRAM)